47 studies found for:    physical | urticaria
Show Display Options
Download search resultsDownload the search results for:
physical | urticaria (47 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting Pathogenesis of Physical Induced Urticarial Syndromes
Conditions: Autoinflammatory Syndromes;   Physical Urticaria
Intervention:
2 Recruiting Cold Urticaria Treatment With Xolair
Condition: Cold Contact Urticaria
Interventions: Drug: Omalizumab;   Drug: Placebo
3 Completed
Has Results
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
Condition: Chronic Urticaria
Interventions: Drug: Omalizumab 75-375 mg;   Drug: Placebo to omalizumab;   Drug: Loratadine;   Drug: Clemastine
4 Completed
Has Results
Observation of Side Effects and Effectiveness of Desloratadine (Aerius) Syrup in Filipino Children (Study P05634)(COMPLETED)
Conditions: Rhinitis, Allergic, Seasonal;   Rhinitis, Allergic, Perennial;   Urticaria
Intervention: Drug: Desloratadine Syrup
5 Completed Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria
Condition: Urticaria
Interventions: Drug: Bilastine;   Drug: Levocetirizine;   Drug: Placebo
6 Recruiting Urticaria Facticia Treatment With Omalizumab (UFO)
Condition: Symptomatic Dermographism
Interventions: Drug: Omalizumab;   Drug: Placebo
7 Completed
Has Results
Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)
Condition: Idiopathic Solar Urticaria
Interventions: Drug: Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209);   Drug: Ti02 pigmentary 3% alone (formula RV3131A-MV1211);   Drug: bisoctrizole 10% alone (formula RV3131A-MV1237);   Drug: Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213);   Drug: Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329);   Drug: Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212);   Drug: Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)];   Drug: V0096 CR vehicle (formula RV3131A-MV1197)
8 Not yet recruiting Efficacy and Safety of Omalizumab in Patients With Severe Acute Urticaria
Condition: Urticaria
Intervention: Drug: omalizumab
9 Recruiting Studies of the Natural History and Pathogenesis and Outcome of Neonatal Onset Multisystem Inflammatory Disease (NOMID/CAPS, DIRA, CRMO, Still s Disease, Behcet s Disease, and Other Undifferentiated Autoinflammatory Diseases)
Conditions: Urticaria;   Arthropathy;   Lymphadenopathy;   Nervous System Anomalies
Intervention:
10 Suspended Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease
Conditions: Nervous System Malformations;   Arthropathy, Neurogenic;   Urticaria;   Papilledema
Intervention:
11 Terminated Efficacy of Rupatadine 5, 10 and 20 Mg in Chronic Idiopathic Urticaria
Condition: Urticaria
Intervention: Drug: RUPATADINE (ANTI-HISTAMINE)
12 Completed Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses
Conditions: Urticaria;   Vasculitis
Intervention: Drug: canakinumab
13 Completed An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540)
Condition: Urticaria
Intervention: Drug: Desloratadine
14 Recruiting Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
Conditions: Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue;   Pyoderma Gangrenosum;   Erosive Pustular Dermatosis of the Scalp;   Sweet's Syndrome;   Behcet's Disease;   Bowel-associated Dermatosis-arthritis Syndrome;   Pustular Psoriasis;   Acute Generalized Exanthematous Pustulosis;   Keratoderma Blenorrhagicum;   Sneddon-Wilkinson Disease;   IgA Pemphigus;   Amicrobial Pustulosis of the Folds;   Infantile Acropustulosis;   Transient Neonatal Pustulosis;   Neutrophilic Eccrine Hidradenitis;   Rheumatoid Neutrophilic Dermatitis;   Neutrophilic Urticaria;   Still's Disease;   Erythema Marginatum;   Unclassified Periodic Fever Syndromes / Autoinflammatory Syndromes;   Dermatitis Herpetiformis;   Linear IgA Bullous Dermatosis;   Bullous Systemic Lupus Erythematosus;   Inflammatory Epidermolysis Bullosa Aquisita;   Neutrophilic Dermatosis of the Dorsal Hands (Pustular Vasculitis);   Small Vessel Vasculitis Including Urticarial Vasculitis;   Erythema Elevatum Diutinum;   Medium Vessel Vasculitis
Intervention: Procedure: Collection of biological samples
15 Completed Bilastine Updosing - Characterization of Underlying Mechanisms
Condition: Cold Contact Urticaria
Intervention: Drug: Bilastine
16 Active, not recruiting A Long-Term Examination of Asthma From Childhood Through Adolescence
Conditions: Asthma;   Dermatitis, Atopic;   Rhinitis;   Urticaria
Intervention:
17 Completed Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria
Condition: Urticaria
Interventions: Drug: Cetirizine;   Drug: Desloratadine;   Drug: Fexofenadine;   Drug: Ebastine;   Drug: Bilastine
18 Completed Phase II Solar Urticaria (SU) Pilot Study
Condition: Solar Urticaria
Intervention: Drug: afamelanotide
19 Recruiting Cold Contact Urticaria Treatment With Rilonacept
Condition: Cold Contact Urticaria
Interventions: Drug: Rilonacept;   Drug: Placebo
20 Completed
Has Results
Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Conditions: Familial Cold Autoinflammatory Syndrome (FCAS);   Familial Cold Urticaria;   Muckle-Wells Syndrome (MWS);   Genetic Diseases, Inborn
Interventions: Drug: rilonacept 160 mg;   Drug: Placebo

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years